Introducing 428Pharma.
Developing the world's first treatment to prevent relapse in depression
Our Mission
-
After treatment of the first episode of depression, ~50% of all patients will relapse
-
This risk increases for every subsequent episode:
-
70% and 90% after a second and third episode respectively
-
-
After a second relapse patients are defined as treatment resistant (TRD)
-
30% of TRD patients attempt suicide in their lifetime
-
Suicide death rate among persons aged 10–24 increased 56% (2007-2017)
-
-
Prevention of relapse can prevent patients becoming treatment resistant and reduce their suicide risk
-
There are currently no treatments that reduce relapse in MDD
Our Product
Escitalopram LAI (Long Acting Injectable)
We have a formulation of the worlds first LAI for prevention of relapse in MDD - potential time to market 2028
-
First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025
-
505(b)(2) truncated development with LOE 2046. PK only approval pathway with FDA
-
Opportunity to out-license end of phase I
